Market open
Climb Bio/$CLYM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Ticker
$CLYM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
10
Website
Climb Bio Metrics
BasicAdvanced
$87M
-
-$1.81
-0.25
-
Price and volume
Market cap
$87M
Beta
-0.25
52-week high
$11.55
52-week low
$1.28
Average daily volume
342K
Financial strength
Current ratio
57.73
Quick ratio
56.775
Total debt to equity
0.027
Management effectiveness
Return on assets (TTM)
-7.15%
Return on equity (TTM)
-42.08%
Valuation
Price to book
0.4
Price to tangible book (TTM)
0.4
Price to free cash flow (TTM)
-4.52
Growth
Earnings per share change (TTM)
23.05%
3-year earnings per share growth (CAGR)
-41.13%
What the Analysts think about Climb Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Climb Bio stock.
Climb Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Climb Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Climb Bio stock?
Climb Bio (CLYM) has a market cap of $87M as of March 12, 2025.
What is the P/E ratio for Climb Bio stock?
The price to earnings (P/E) ratio for Climb Bio (CLYM) stock is 0 as of March 12, 2025.
Does Climb Bio stock pay dividends?
No, Climb Bio (CLYM) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Climb Bio dividend payment date?
Climb Bio (CLYM) stock does not pay dividends to its shareholders.
What is the beta indicator for Climb Bio?
Climb Bio (CLYM) has a beta rating of -0.25. This means that it has an inverse relation to market volatility.